PANDoRA – PANcreatic Disease ReseArch Consortium – is an international pancreatic disease research consortium that was founded in 2013 under the leadership of Dr. Federico Canziano of the DKFZ in Heidelberg. The founding members include Prof. Pavel Souček, head of the Laboratory of Pharmacogenomics, and since 2020, a member of the consortium is also prof. Václav Liška from the Laboratory of Cancer Treatment and Tissue Regeneration. Both laboratories, operating in the Biomedical Center of the Faculty of Medicine, Charles University in Pilsen, are part of the NICR.
The main objectives of the PANDoRA consortium include research into the relationship between the risk of pancreatic cancer and individual differences in genetic make-up and analysis of molecular factors correlated with disease progression, patient prognosis and response to cancer treatment. These objectives align very well with the priorities of the NICR research programs 3: Biomarkers of cancers and cancer diagnostics. The two aforementioned laboratories of Pavel Souček and Václav Liška are involved in their implementation. More information about the PANDoRA consortium and the results of joint research can be found from a recent publication evaluating its 10 years of existence, as well as from more than 40 professional publications available on PubMed.
